New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 13, 2013
13:09 EDTNAVB, CAHFDA approves Navidea Lymphoseek injection for use in lymphatic mapping
Navidea Biopharmaceuticals (NAVB) announced U.S. Food and Drug Administration approval of Lymphoseek Injection, a novel product indicated for use in lymphatic mapping procedures to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma. Lymphoseek will be sold and distributed in the U.S. on an exclusive basis by Cardinal Health (CAH).
News For NAVB;CAH From The Last 14 Days
Check below for free stories on NAVB;CAH the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 11, 2014
07:32 EDTCAHCardinal Health appoints Michael C. Kaufmann as CFO
Cardinal Health has named Michael C. Kaufmann, 51, CFO effective Nov. 11. This follows the previously announced planned retirement of current CFO Jeffrey W. Henderson, 49. Jon Giacomin, 49, has been named to the role of CEO of the Pharmaceutical segment, currently held by Mike Kaufmann, also effective Nov. 11.
September 4, 2014
07:32 EDTNAVBNavidea enters Lymphoseek development and commercialization agreement for China
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use